A Mendelian randomization study of the effect of type-2 diabetes on coronary heart disease

[1]  Vincenzo Forgetta,et al.  Mendelian randomisation applied to drug development in cardiovascular disease: a review , 2014, Journal of Medical Genetics.

[2]  Michael E. Miller,et al.  Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial , 2014, The Lancet.

[3]  N. Samani,et al.  Mendelian randomization studies in coronary artery disease. , 2014, European heart journal.

[4]  M. Fornage,et al.  Title: Polygenic type 2 diabetes prediction at the limit of common variant detection Running title: T2D polygenic prediction , 2014 .

[5]  Inês Barroso,et al.  Impact of Type 2 Diabetes Susceptibility Variants on Quantitative Glycemic Traits Reveals Mechanistic Heterogeneity , 2014, Diabetes.

[6]  M. Laakso,et al.  Insulin resistance and hyperglycaemia in cardiovascular disease development , 2014, Nature Reviews Endocrinology.

[7]  C. Langefeld,et al.  Analysis of common and coding variants with cardiovascular disease in the diabetes heart study , 2014, Cardiovascular Diabetology.

[8]  F. Wolf,et al.  Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers , 2016, Clinical Diabetes.

[9]  Wei Bao,et al.  Systematic Reviews and Meta-and Pooled Analyses Predicting Risk of Type 2 Diabetes Mellitus with Genetic Risk Models on the Basis of Established Genome-wide Association Markers : A Systematic Review , 2013 .

[10]  Tanya M. Teslovich,et al.  Common variants associated with plasma triglycerides and risk for coronary artery disease , 2013, Nature Genetics.

[11]  A. Butterworth,et al.  Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data , 2013, Genetic epidemiology.

[12]  Mark I. McCarthy,et al.  Mendelian Randomization Studies Do Not Support a Causal Role for Reduced Circulating Adiponectin Levels in Insulin Resistance and Type 2 Diabetes , 2013, Diabetes.

[13]  Andrew D. Johnson,et al.  Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease. , 2013, The American journal of clinical nutrition.

[14]  S. Thompson,et al.  Use of allele scores as instrumental variables for Mendelian randomization , 2013, International journal of epidemiology.

[15]  Tom M Palmer,et al.  Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts , 2013, BMJ.

[16]  Florian Kronenberg,et al.  The shared allelic architecture of adiponectin levels and coronary artery disease. , 2013, Atherosclerosis.

[17]  B. Nordestgaard,et al.  Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.

[18]  D. Lau,et al.  The Canadian Diabetes Association 2013 clinical practice guidelines-raising the bar and setting higher standards! , 2013, Canadian journal of diabetes.

[19]  Ross M. Fraser,et al.  Sex-stratified Genome-wide Association Studies Including 270,000 Individuals Show Sexual Dimorphism in Genetic Loci for Anthropometric Traits , 2013, PLoS genetics.

[20]  Christian Gieger,et al.  The Role of Adiposity in Cardiometabolic Traits: A Mendelian Randomization Analysis , 2013, BDJ.

[21]  Michael J Pencina,et al.  Genetic Predisposition to Higher Blood Pressure Increases Coronary Artery Disease Risk , 2013, Hypertension.

[22]  P. Grande,et al.  Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta‐analysis , 2013, Journal of internal medicine.

[23]  J. Danesh,et al.  Large-scale association analysis identifies new risk loci for coronary artery disease , 2013 .

[24]  V. Basevi.  Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[25]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[26]  Tanya M. Teslovich,et al.  Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways , 2012, Nature Genetics.

[27]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[28]  Tanya M. Teslovich,et al.  Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes , 2012, Nature Genetics.

[29]  Mark I McCarthy,et al.  A Mendelian Randomization Study , 2012 .

[30]  George Davey Smith,et al.  Using multiple genetic variants as instrumental variables for modifiable risk factors , 2012, Statistical methods in medical research.

[31]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[32]  N. Timpson,et al.  Mendelian Randomization: Application to Cardiovascular Disease , 2012, Current Hypertension Reports.

[33]  Christian Gieger,et al.  Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk , 2011, Nature.

[34]  Kasper Lage,et al.  Pervasive Sharing of Genetic Effects in Autoimmune Disease , 2011, PLoS genetics.

[35]  N. Mehta.  Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. , 2011, Circulation. Cardiovascular genetics.

[36]  B. Norrving,et al.  Global atlas on cardiovascular disease prevention and control. , 2011 .

[37]  R. Frikke-Schmidt,et al.  Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. , 2010, The Journal of clinical endocrinology and metabolism.

[38]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[39]  Ayellet V. Segrè,et al.  Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis , 2010, Nature Genetics.

[40]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.

[41]  The Emerging Risk Factors Collaboration.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.

[42]  Michael E. Miller,et al.  ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .

[43]  J. Shaw,et al.  Global estimates of the prevalence of diabetes for 2010 and 2030. , 2010, Diabetes research and clinical practice.

[44]  J. Liao,et al.  Genetically elevated C-reactive protein and ischemic vascular disease , 2009, Current atherosclerosis reports.

[45]  N. Sattar,et al.  Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials , 2009, The Lancet.

[46]  S. Havas.  The ACCORD Trial and control of blood glucose level in type 2 diabetes mellitus: time to challenge conventional wisdom. , 2009, Archives of internal medicine.

[47]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[48]  Darren K Mcguire,et al.  The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context , 2009, Diabetes & vascular disease research.

[49]  S. Schinner.  Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .

[50]  S. Schinner,et al.  Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .

[51]  Andrew D. Johnson,et al.  SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap , 2008, Bioinform..

[52]  Baiju R. Shah,et al.  Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines , 2008, Canadian Medical Association Journal.

[53]  Nikolaos A Patsopoulos,et al.  Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. , 2008, International journal of epidemiology.

[54]  C. Gieger,et al.  Lifelong Reduction of LDL-Cholesterol Related to a Common Variant in the LDL-Receptor Gene Decreases the Risk of Coronary Artery Disease—A Mendelian Randomisation Study , 2008, PloS one.

[55]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[56]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[57]  George Davey Smith,et al.  Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[58]  Executive Summary: Standards of Medical Care in Diabetes—2008 , 2008, Diabetes Care.

[59]  Jonathan A C Sterne,et al.  The impact of residual and unmeasured confounding in epidemiologic studies: a simulation study. , 2007, American journal of epidemiology.

[60]  Explore Configuring.  A Simulation Study to , 2004 .

[61]  Stephen W. Sorensen,et al.  Lifetime risk for diabetes mellitus in the United States. , 2003, JAMA.

[62]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[63]  Plamen Nikolov,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[64]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[65]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[66]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[67]  George Davey Smith,et al.  Meta-analysis of randomised controlled trials , 1997, The Lancet.

[68]  P. Rothwell,et al.  Meta-analysis of randomised controlled trials , 1997, The Lancet.

[69]  Robert C. Wolpert,et al.  A Review of the , 1985 .